FDA Grants Priority Review to Enhertu for HER2‑Positive Early Breast Cancer With Residual Disease
- March 11, 2026
Two Intellia Clinical Trials Released by the FDA
Gene Therapy Setback: REGENXBIO’s RGX-121 Faces Regulatory Hurdles in Ultra-Rare Disease Treatment
Serina Therapeutics Begins First-in-Patient Dosing in Phase 1b Trial of SER‑252 for Advanced Parkinson’s Disease
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Have you been impacted by Tardive Dyskinesia? Patient Worthy is looking for personal stories to help others feel supported and inspired. Your experience could make a meaningful difference! Share your patient journey with us here: bit.ly/4dV7gru
#tardivedyskinesia #TD #yourstorymatters #shareyourstory #PatientWorthy
CureDuchenne @PADUFA @FDAAs an early funder of Capricor Therapeutics, CureDuchenne is pleased to share that the FDA has set the PDUFA target action date for August 22, 2026, as the deadline to review approval of deramiocel for Duchenne muscular dystrophy. Deramiocel is a cell therapy that exerts immunomodulatory and anti-fibrotic actions on cardiac and skeletal muscle.
Read more here: cureduchenne.org/research/capricor-announces-the-fda-to-review-deramiocel-for-duchenne-by-august-...
Capricor Therapeutics, Inc. #DMD #duchenne
Charcot-Marie-Tooth AssociationThe Walk 4 CMT 2026 season is here!🧡
Join the nationwide movement to help change the future for people living with CMT. Every step and every mile brings us closer to treatments and a cure.
📍 Find your event and register today → walkcycle.cmtausa.org
